ACE1708

**ACE1708** is an investigational allogeneic PD-L1-targeted cell therapy from Acepodia that uses the company's Antibody-Cell Conjugation technology to attach a PD-L1-binding antibody to the surface of donor-derived cytotoxic immune cells. Public descriptions have characterized ACE1708 as a PD-L1-directed ACC-based program using either natural killer cells or, more specifically in later company descriptions, γδ2 T cells, intended to redirect innate-like effector cells toward PD-L1-expressing tumors and induce tumor-cell killing. The program has been described for oncology applications including solid tumors and hematologic malignancies such as lymphoma, with anti-tumor activity reported in preclinical studies; however, more recent public pipeline materials emphasize other Acepodia programs and do not prominently list ACE1708, suggesting it remains preclinical, inactive, or possibly deprioritized.

Other names

PD-L1-targeted ACC-γδ2 T-cell therapyPD-L1-targeted ACC-NK cell therapyPD-L-1-targeted ACC-NK cell therapyPD-L 1-targeted ACC-NK cell therapy